Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement

Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform With The Goal Of Assessing Patient Responsiveness To Fosciclopirox Foster City, Calif. and Kansas City, Mo., December 1, 2021 – Notable Labs, Inc. (Notable), a clinical-stage predictive precision therapeutics company and CicloMed LLC (CicloMed), a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of […]

Notable Expands Executive Leadership Team with Appointment of Christopher Whitmore as Chief Financial Officer

Notable Expands Executive Leadership Team with Appointment of Christopher Whitmore as Chief Financial Officer

Foster City, Calif., November 23, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, today announced the appointment of Chris Whitmore as Chief Financial Officer. In this role, Mr. Whitmore will be a key member of the executive leadership team and will lead Notable’s financial strategy, planning […]

Clinical Data on the Notable Predictive Precision Medicines Platform Presented at the 63rd ASH Annual Meeting

Clinical Data on the Notable Predictive Precision Medicines Platform Presented at the 63rd ASH Annual Meeting

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platformto Accelerate Clinical Development and Maximize Patient Outcomes Foster City, Calif., November 22, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, today announced two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. “These two clinical […]

Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib

Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform to Accelerate Clinical Trial Timelines and Maximize Patient Outcomes Volasertib is a PLK-1 inhibitor with therapeutic potential across a range of tumor types Foster City, Calif., November 11, 2021 – Notable Labs, Inc. (Notable), a pioneer and developer of predictive precision medicines, has obtained worldwide rights […]

Notable Labs to Attend BIO Digital 2021 Highlighting Predictive Technology Platform for Oncology

Notable Labs to Attend BIO Digital 2021 Highlighting Predictive Technology Platform for Oncology

FOSTER CITY, CA – June 10, 2021 — Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced that it will be attending BIO Digital 2021, a key international biotech partnering event held virtually on June 14-18. During the conference Notable […]

Notable Labs to Present at ASCO 2021 Highlighting Prediction Technology Platform

Notable Labs to Present at ASCO 2021 Highlighting Prediction Technology Platform

FOSTER CITY, CA – June 4, 2021 — Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced top-line results from its clinical response prediction technology platform in a pediatric acute myeloid leukemia (AML) study to be presented at the 2021 […]

Notable Names Dr. Thomas A. Bock as CEO

Notable Names Dr. Thomas A. Bock as CEO

FOSTER CITY, CA – March 31, 2021 – Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced the appointment of Thomas A. Bock, MD, MBA, as Chief Executive Officer.

Notable Labs to Present Analysis of Hematologic Oncology Drug Sensitivity Data

Notable Labs to Present Analysis of Hematologic Oncology Drug Sensitivity Data

FOSTER CITY, CA – January 26, 2021 – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is hosting a live webinar on February 9th to unveil their integrative data platform.

Notable Labs to present at Biotech Showcase™ Digital 2021

Notable Labs to present at Biotech Showcase™ Digital 2021

FOSTER CITY, CA – January 8, 2021 – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is participating in Biotech Showcase™ 2021 and will be presenting the strategic plan for long-term growth.

Join Notable Labs at the 62nd ASH Annual Meeting – Dec 5-8, 2020

Join Notable Labs at the 62nd ASH Annual Meeting – Dec 5-8, 2020

FOSTER CITY, CA – Dec 3, 2020 – Dr. Michael Spinner, from Stanford University, Department of Medicine, Division of Oncology, will present at the 2020 Virtual ASH Annual Meeting an update to the recently published article in Blood Advances.

Notable Labs Announces Partnership With All4Cure

Notable Labs Announces Partnership With All4Cure

FOSTER CITY, CA and SEATTLE; Oct. 28, 2020 (Business Wire) – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, today announced their partnership.

Notable Labs Announces Addition of Thomas Bock to Board of Directors

Notable Labs Announces Addition of Thomas Bock to Board of Directors

FOSTER CITY, CA – Oct. 13, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Thomas A. Bock to its board of directors.

Notable Labs Enters Into Partnership With myTomorrows

Notable Labs Enters Into Partnership With myTomorrows

FOSTER CITY, CA – Sep. 24, 2020 – Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.

Notable Launches New Clinical Study With Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance

Notable Launches New Clinical Study With Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance

FOSTER CITY, CA – Aug. 06, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced a new precision oncology study with Washington University School of Medicine in St. Louis, exploring the feasibility of ex vivo drug screening to predict sensitivity and resistance to chemotherapy, and to identify novel synergies across a broad panel of anti-cancer therapies.

Notable Appoints Biotech Veteran Joseph Wagner PhD as Chief Scientific Officer

Notable Appoints Biotech Veteran Joseph Wagner PhD as Chief Scientific Officer

FOSTER CITY, CA – July 08, 2020 (GLOBE NEWSWIRE) – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that Joseph Wagner, PhD, has joined the company as Chief Scientific Officer. Dr. Wagner.

Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

FOSTER CITY, CA – June 23, 2020 (GLOBE NEWSWIRE) — Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that the results of a Stanford study using its drug sensitivity screening platform have been published in Blood Advances (June 23, 2020; Volume 4, Issue 12).

Notable and MDS Foundation Announce Partnership to Collaborate on Clinical MDS Trials and Advance Drug Therapies for MDS Patients

Notable and MDS Foundation Announce Partnership to Collaborate on Clinical MDS Trials and Advance Drug Therapies for MDS Patients

FOSTER CITY, CA – April 30, 2020 — Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, announced a partnership today with the MDS Foundation. MDS Foundation (MDSF) provides insight and information to families on upcoming clinical trials for myelodysplastic syndrome (MDS). As part of the partnership, Notable […]

Notable Announces Leadership Team Expansion

Notable Announces Leadership Team Expansion

FOSTER CITY, CA – April 09, 2020 (GLOBE NEWSWIRE) — Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its board has appointed veteran life science executive Laurie Heilmann as Chief Executive Officer. She succeeds founder Matt De Silva who will remain a member of Notable’s […]

MedTech Notable Labs launches rolling blood cancer trial to test its AI system

MedTech Notable Labs launches rolling blood cancer trial to test its AI system

FOSTER CITY, CA – January 22, 2020 — Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, is launching its first self-sponsored clinical trial, designed from the ground up to help validate its cancer patient matching platform over the long term.